2-Azaniumyl-3-propan-2-yloxypropanoate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-Azaniumyl-3-propan-2-yloxypropanoate
• 化学式: C₆H₁₃NO₃
• 分子量: 147.17
• InChiKey: RWPNRIDPFQODSJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.7
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  72.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF<br/>[FR] INHIBITEURS D'ALK5, CONJUGUÉS ET LEURS UTILISATIONS
  申请人：SILVERBACK THERAPEUTICS INC

  公开号：WO2022006340A1

  公开（公告）日：2022-01-06

  ALK5 inhibitor compounds, conjugates, and pharmaceutical compositions for use in the treatment of disease, such as cancer, are disclosed herein. Additionally, compounds incorporated into a conjugate with an antibody construct are described herein.The disclosed compoundsand conjugates are useful, among other things, in the treating of cancer and fibrosis and modulating ALK5.

  本文披露了用于治疗疾病（如癌症）的ALK5抑制剂化合物、结合物和药物组合物。此外，本文还描述了与抗体构造物结合的化合物。所披露的化合物和结合物在治疗癌症和纤维化以及调节ALK5等方面非常有用。
• PROSTAGLANDIN F2 ALPHA DERIVATIVES FOR DECREASING INTRAOCULAR PRESSURE
  申请人：GURUS BIOPHARM LIMITED LIABILITY COMPANY

  公开号：US20210230111A1

  公开（公告）日：2021-07-29

  The invention relates to clinical chemistry, in particular, to new biologically active compounds amide derivatives of prostaglandin F2α. These compounds have low cytotoxicity and are capable of stimulating formation of endogenous nitrogen oxide in mammal cells. Synthesis of such compounds promotes expansion of nomenclature of biologically active derivatives of prostaglandin F2α capable of reducing intraocular pressure.

  这项发明涉及临床化学，特别是新的生物活性化合物——前列腺素F2α酰胺衍生物。这些化合物具有低细胞毒性，并能够刺激哺乳动物细胞内源性一氧化氮的形成。合成这类化合物有助于扩展能够降低眼内压的生物活性前列腺素F2α衍生物的命名。
• METALLOENZYME INHIBITOR COMPOUNDS
  申请人：VIAMET PHARMACEUTICALS, INC.

  公开号：US20150353546A1

  公开（公告）日：2015-12-10

  The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.

  这个发明描述了具有金属酶调节活性的化合物，并且提供了治疗由这些金属酶介导的疾病、疾病症状或疾病障碍的方法。
• New compounds
  申请人：Aktiebolaget Hässle

  公开号：EP0353211A1

  公开（公告）日：1990-01-31

  Compounds having a renin inhibitory effect and having the formula where R¹ = H; lower alkyl (1-3 carbons) R² = straight or branched lower alkyl or alkenyl (1-6 carbons), optionally substituted with lower alkoxy, cyano, fluoro, lower thioalkyl; cycloalkyl (3-7 carbons); aryl (6-10 carbons); cycloalkylalkyl (4-9 carbons); arylalkyl (7-11 carbons) R³ = straight or branched lower alkyl (3-6 carbons); cycloalkylalkyl (4-11 carbons); arylalkyl (7-11 carbons) R⁴ = H; straight or branched lower alkyl (1-5 carbons) R⁵ = straight or branched lower alkyl (1-5 carbons); cycloalkyl (3-7 carbons); aryl (6-10 carbons); arylalkyl (7-11 carbons); cycloalkylalkyl (4-8 carbons) q = 0-2 o = 0-2 p = 0-2 n = 0-2 X = CH; N Z = O; CH(R⁸); absent W = O; CH(R⁸); absent R⁶ = straight or branched lower alkyl (1-6 carbons); cycloalkyl (3-7 carbons); aryl (6-10 carbons) either as such or substituted by 1-3 substituents selected from: halogen (e.g. F,Cl), lower alkoxy (1-3 carbons e.g. methoxy), nitro, hydroxy, lower alkyl (1-3 carbons e.g. methyl), cyano R⁷ = as defined for R⁶ R⁸ = lower alkyl (1-3 carbons). Processes for preparation and pharmaceutical preparations for such compounds and methods for treatment of heart disorders with such compounds are further disclosed.

  具有肾素抑制作用的化合物，其式如下 其中 R¹ = H；低级烷基（1-3 个碳原子） R² = 直链或支链低级烷基或烯基（1-6 个碳），任选被低级烷氧基、氰基、氟基、低级硫代烷基取代；环烷基（3-7 个碳）；芳基（6-10 个碳）；环烷基烷基（4-9 个碳）；芳基烷基（7-11 个碳） R³ = 直链或支链低级烷基（3-6 个碳原子）；环烷基烷基（4-11 个碳原子）；芳基烷基（7-11 个碳原子） R⁴ = H；直链或支链低级烷基（1-5 个碳原子） R⁵ = 直链或支链低级烷基（1-5 个碳原子）；环烷基（3-7 个碳原子）；芳基（6-10 个碳原子）；芳烷基（7-11 个碳原子）；环烷基烷基（4-8 个碳原子） q = 0-2 o = 0-2 p = 0-2 n = 0-2 X = CH；N Z = O；CH(R⁸)；无 W = O；CH(R⁸)；无 R⁶ = 直链或支链低级烷基（1-6 个碳原子）；环烷基（3-7 个碳原子）；芳基（6-10 个碳原子），可为直链或支链低级烷基，也可被 1-3 个取代基取代，这些取代基选自：卤素（如 F、Cl）、低级烷氧基（1-3 个碳原子，如甲氧基）、硝基、羟基、低级烷基（1-3 个碳原子，如甲基）、氰基。 R⁷ = 与 R⁶ 的定义相同 R⁸ = 低级烷基（1-3 个碳原子）。 进一步公开了此类化合物的制备工艺和药物制剂，以及用此类化合物治疗心脏疾病的方法。
• US9663488B2
  申请人：——

  公开号：US9663488B2

  公开（公告）日：2017-05-30